| 包装 | 价格(元) |
| 500 µg | 电议 |
| 1mg | 电议 |
| Canonical SMILES | FC1=CC=C([C@H]2[C@H](C([2H])([2H])OC3=CC(OCO4)=C4C=C3)C([2H])([2H])NC([2H])([2H])C2)C=C1.Cl |
| 分子式 | C19H14D6FNO3• HCl |
| 分子量 | 371.9 |
| 溶解度 | DMF: 33mg/mL,DMSO: 20mg/mL,Ethanol: 20mg/mL |
| 储存条件 | -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Paroxetine-d6is intended for use as an internal standard for the quantification of paroxetine by GC- or LC-MS. Paroxetine is a selective serotonin reuptake inhibitor (SSRI; Ki= 0.04 nM).1It is selective for the serotonin transporter (SERT) over the dopamine and norepinephrine transporters (Kis = 400 and 90 nM, respectively) as well as the serotonin (5-HT) receptor subtypes 5-HT1Aand 5-HT2A, the histamine H1receptor, α1- and α2-adrenergic receptors (α2-ARs), and muscarinic acetylcholine receptors (mAChRs; Kis = 21,168, 6,320, 13,746, 995, 3,915, and 42 nM, respectively).1,2Paroxetine (5 mg/kg) decreases immobility time in the forced swim test in mice.3Formulations containing paroxetine have been used in the treatment of depression, obsessive-compulsive disorder (OCD), panic disorder, social and generalized anxiety disorders, and post-traumatic stress disorder (PTSD). 1.Mattson, R.J., Catt, J.D., Denhart, D.J., et al.Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitorsJ. Med. Chem.48(19)6023-6034(2005) 2.Owens, M.J., Neal, W., Plott, S.J., et al.Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolitesJ. Pharmacol. Exp. Ther.283(3)1305-1322(1997) 3.Sugimoto, Y., Tagawa, N., Kobayashi, Y., et al.Involvement of the sigma1 receptor in the antidepressant-like effects of fluvoxamine in the forced swimming test in comparison with the effects elicited by paroxetineEur. J. Pharmacol.696(1-3)96-100(2012) |
m.cnreagent.com